The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells
© Park et al.; licensee BioMed Central. 2015
Accepted: 26 December 2014
Published: 23 January 2015
Epigenetic modifications play a critical role in the regulation of all DNA-based processes, such as transcription, repair, and replication. Inappropriate histone modifications can result in dysregulation of cell growth, leading to neoplastic transformation and cell death. Renal tumors have been shown to have a higher global methylation percentage and reduced histone acetylation. Preclinical models have revealed that histone gene modifiers and epigenetic alterations play important roles in renal cell carcinoma (RCC) tumorigenesis. Recently, a novel HDAC inhibitor, N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), has been introduced as an example of a new class of anti-cancer agents. The anti-cancer activity of HNHA and the underlying mechanisms of action remain to be clarified.
The MTS assay using a panel of RCC cells was used to evaluate the anti-proliferative effects of HNHA. The established HDAC inhibitors, SAHA and TSA, were used for comparison. Western blotting analysis was performed to investigate the acetylation of histone H3 and the expression of apoptotic markers in vitro and in vivo. Subcellular fractionation was performed to evaluate expression of Bax and cytochrome c in the cytosol and mitochondria, and also translocation of cytochrome c from the cytoplasm to the nucleus. A confocal microscopic evaluation was performed to confirm inhibition of cell proliferation, induction of apoptosis, and the nuclear translocation of cytochrome c in RCC cells.
In this study, we investigated the apoptosis-inducing activity of HNHA in cultured kidney cancer cells. Apoptosis in the HNHA-treated group was induced significantly, with marked caspase activation and Bcl-2 suppression in RCC cells in vitro and in vivo. HNHA treatment caused cytochrome c release from mitochondria, which was mediated by increased Bax expression and caspase activation. HNHA also induced nuclear translocation of cytochrome c, suggesting that HNHA can induce caspase-independent nuclear apoptosis in RCC cells. An in vivo study showed that HNHA had greater anti-tumor and pro-apoptotic effects on RCC xenografts than the established HDAC inhibitors.
HNHA has more potent anti-tumor activity than established HDAC inhibitors. Its activities are mediated by caspase-dependent and cytochrome-c-mediated apoptosis in RCC cells. These results suggest that HNHA may offer a new therapeutic approach to RCC.
KeywordsHNHA Histone deacetylase (HDAC) inhibitor Renal cell carcinoma (RCC) Cytochrome c Apoptosis
The initiation and progression of cancer, traditionally seen as a genetic disease, is now known to involve epigenetic abnormalities along with genetic alterations . Epigenetic modifications, defined as heritable changes in gene expression that are not due to any alteration in the DNA sequence, play a key role in the regulation of all DNA-based processes, such as transcription, repair, and replication . Consequently, abnormal expression patterns or genomic alterations in chromatin regulators have profound results and can lead to the development and maintenance of various cancer types .
One epigenetic modification common in several tumors is the modification of histones. Histones are the chief protein components of chromatin, acting not simply as spools around which DNA is coiled, but also as regulators of chromatin dynamics . Because histone modifications are proposed to affect chromosome function, inappropriate histone modifications would be expected to result in dysregulation of cell growth, leading to neoplastic transformation or cell death [3–6]. The histone-modifying enzymes, histone acetyltransferases—which include histone deacetylases (HDACs) and histone methyltransferases (HMTs)—regulate these modification processes.
HDACs are important regulators of gene expression that remove acetyl groups from histones enzymatically. Numerous studies have demonstrated aberrant expression of HDACs in human tumors, and the expression levels of HDAC1, −5, and −7 serve as molecular biomarkers of tumor versus normal tissue. Moreover, in several cancer types, overexpression of individual HDACs correlates with significant decreases in both disease-free and overall survival [7–11]. Recent studies revealed that HDAC plays an important role in carcinogenesis and the overexpression of HDACs has been linked to key events in the repression of the tumor suppressor gene CDKN1A, encoding p21, and genes encoding DNA damage repair enzymes, such as BRCA1 and ATR .
Renal cell carcinoma (RCC) is a malignancy of the kidney that originates in the proximal renal tubule and accounts for ~3% of all cancers . Although the incidence of small renal masses is high, approximately one in three patients presents with metastatic disease . RCC is highly resistant to chemotherapy and radiotherapy; non-specific immunotherapy using interleukins and interferons are used as a standard treatment; however, the response rate is low.
Recent clarification of the molecular mechanisms of RCC has permitted tremendous progress in the development and approval of multiple targeted agents for the treatment of advanced RCC. Therapies targeted at the “vascular endothelial growth factor” (VEGF) and “mammalian target of rapamycin” (mTOR) pathways now represent the standard of care in metastatic RCC [13,14]. However, durable therapeutic responses to these therapies are uncommon, and the prognosis of RCC remains dismal.
Recent molecular investigations revealed that RCC has a higher percentage of global methylation and reduced histone acetylation, compared with non-tumor counterpart cells . Several studies have demonstrated that histone deacetylases are highly expressed and decreased acetylation of histone H3 is a common alteration in RCC [16,17].
The use of massively parallel sequencing technologies enabled the discovery of additional common epigenetic modifications. Preclinical models have revealed that histone gene modifiers and epigenetic alterations may play important roles in RCC tumorigenesis and progression. In vitro analyses of renal tumor cell lines treated with vorinostat or ritonavir, alone and in combination, showed consistent dephosphorylation of Rb along with reduced HDAC1 expression and an increase in the sub-G1 fraction with combination treatment .
The biological outcome of HDAC inhibition is dependent on the HDAC specificity of the compound and the intrinsic operation of the cell-signaling pathways. Recently, N-hydroxy-7-(2-naphthylthio) hepatonomide (HNHA) has been introduced. It is a novel HDAC inhibitor that potently suppresses histone hypoacetylation and downregulation of HDAC target genes . In this first study introducing HNHA, HNHA exhibited potent HDAC-inhibitory activity with IC50 values of 0.1 lM. In contrast, other compounds containing substituted nitrogen or oxygen for sulfur atom and having different lengths of alkyl chain (C5 and C7) showed weaker activity than that of HNHA. Moreover, compounds containing different zinc-chelating motifs such as an aminophenyl group or a hydroxy-acetylamino group had a weaker HDAC-inhibitory activity . HNHA shows strong anti-cancer activity with pharmacological properties superior to those of the known HDAC inhibitor SAHA in human fibrosarcoma and breast cancer cells [19,20]. Here, we investigated this novel HDAC inhibitor and its mitochondrion-targeted actions in RCC and discuss the role of HNHA in induction of apoptotic cell death pathways in RCC.
The human RCC cell lines Caki-1 and A-498 were obtained from the American Type Culture Collection and maintained in McCoy’s 5A medium (Hyclone, Thermo Fisher Scientific), supplemented with 10% fetal bovine serum (FBS) and in minimal essential medium (MEM; Invitrogen), supplemented with 10% FBS and 2 mM L-glutamine. Cells were cultured at 37°C in a humidified atmosphere with 5% CO2. For all experiments, cell lines were maintained for no more than 2 months.
Cell viability assay
Cell proliferation was measured using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cells were seeded in 96-well plates at 5 × 103 per well and incubated overnight to 70% confluency. Drug was added at 0-120 μM final concentrations. After drug treatment, cells were incubated for 0, 12, 24, 36, 48, 60, and 72 h and cell viability was then measured using the MTT reagent at 490 nm according to the manufacturer’s protocol. Briefly, MTT reagent (10 μL) was added to each well (final concentration, 0.5 mg/mL) and the plate was incubated at 37°C. After 4 h, 100 μL of solubilization solution (10% SDS) were added to each well and the plate was incubated for 2 h. Data are presented as mean percentages of vehicle-treated cell proliferation ± SEM of triplicate experiments.
To assay apoptosis, cells were fixed with 4% paraformaldehyde after 48 h of treatment and stained using a terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) kit (Promega, Madison, WI). Apoptotic (fluorescent green) and total cells were counted under a fluorescence microscope and data were recorded. Images were obtained using a confocal microscope (LSM Meta 700, Carl Zeiss, Oberkochen, Germany) and analyzed using the Zeiss LSM Image Browser software (ver. 4.2.0121).
To assess cytochrome c release, cells were incubated with 0.05% digitonin in an isotonic sucrose buffer (250 mM sucrose, 10 mM HEPES-NaOH, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, and 0.5 mM phenylmethylsulfonyl fluoride; pH 7.2) at room temperature. At this concentration, digitonin permeabilizes the plasma membrane but not the mitochondrial membrane. The digitonin extract was collected as the cytosolic fraction for immunoblot analysis. To examine Drp1 translocation to mitochondria during apoptosis, cells were collected in ice-cold isotonic sucrose buffer by gentle scraping and homogenized using a Wheaton homogenizer. The homogenate was centrifuged (1000 g) to remove debris and nuclei; the supernatant was subjected to a further centrifugation step (10,000 g) to yield the mitochondrial fraction. All homogenization and centrifugation procedures were conducted at 4°C.
Western blotting analysis
Cells were washed twice with cold phosphate-buffered saline and lysed on ice with RIPA buffer (Thermo Fisher Scientific, Suwanee, GA, USA) following the manufacturer’s protocol. Protein concentrations were determined by BCA assay (Pierce Biotechnology, Rockford, IL). Equal amounts of protein (20 μg) were separated in 8-10% SDS-polyacrylamide gels; the resolved proteins were then electro-transferred onto PVDF membranes (Millipore, Bedford, MA). The membranes were subsequently blocked with 5% nonfat milk in TBST for 1 h at room temperature and incubated with appropriate concentrations of primary antibodies—acetyl-histone H3 and histone H3 (Abcam, Cambridge, UK), acetyl-α-tubulin and α-tubulin (Abcam), Bax (Novus Biologicals, Littleton, CO, USA), p53 (Abcam), p21 (Abcam), Apaf-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CDK-4 (Cell Signaling Technology, Beverly, MA, USA), CDK-6 (Cell Signaling Technology), cyclin D1(Cell Signaling Technology), caspase-3 (Santa Cruz), caspase-7 (Santa Cruz), Bcl-2 (Santa Cruz), p-IκB (Abcam), cytochrome c (Abcam), and β-actin (Santa Cruz)—overnight at 4°C. The membranes were then washed three times with TBST and probed with the corresponding secondary antibodies conjugated to HRP (Santa Cruz) at room temperature for 1 h. After washing, blots were developed with ECL reagents (Pierce, Rockford, US) and exposed to Kodak X-OMAT AR Film (Eastman Kodak, Rochester, US) for 3 min.
Human kidney cancer cell xenograft
Animals were maintained under specific pathogen-free (SPF) conditions. All experiments were approved by the Animal Experiment Committee of Yonsei University. Human kidney cancer cells (1.0 × 107/mouse) were cultured in vitro and injected subcutaneously into the upper left flank region of the mice. The mice were maintained at 22°C with a 12/12-h light/dark cycle and access to food and water ad libitum. After 10 days, tumor-bearing mice were grouped randomly (n = 10/group) and an intraperitoneal injection of the three drugs (SAHA, TSA, and HNHA) was administered once every 2 days for a total of six injections (30 mg/kg per mouse) when the complete tumor size reached [4/3 × π × (0.7 × 0.4 cm)3 × ½]. Tumor size was measured every other day using calipers. Tumor volume was estimated using the following formula 4/3 × π × (a cm × b cm)3 × ½, where a and b are the two perpendicular diameters. SAHA, TSA, and HNHA doses were chosen based on published studies HDAC inhibitor [20–22].
In vivo toxicity study
In vivo toxicity assays were performed using BALB/c nude mice. Six-week-old mice were caged for 1 week for acclimatization. Each group of 25 mice was injected intraperitoneally with SAHA, TSA, or HNHA at a dose of 30 mg/kg per mouse. The animals were monitored regularly for external signs of toxicity or lethality.
All tissues were fixed in 10% neutral-buffered formalin and embedded in paraffin wax using standard protocols. Tissue sections (5 μm) were dewaxed and antigen retrieval was performed in citrate buffer (pH 6), using an electric pressure cooker set at 120°C for 5 min. Sections were incubated for 5 min in 3% hydrogen peroxide to quench endogenous tissue peroxidase. The primary monoclonal antibody was directed against cytochrome c (Abcam, Cambridge, UK), and was diluted 1:100with phosphate-buffered saline. All tissue sections were counterstained with hematoxylin, dehydrated, and mounted.
Statistical analyses were performed using the GraphPad Prism software (GraphPad Software Inc., La Jolla, CA, USA). Immunohistochemistry results were subjected to one-way ANOVA followed by a Bonferroni post hoc test. Values are expressed as means ± SEM. P values < 0.05 were considered to indicate statistical significance.
HNHA induced histone H3 acetylation in RCC cells
HNHA suppressed RCC tumor cell proliferation
IC 50 (half maximal inhibitory concentration) determination using a cell proliferation assay
Cell proliferation IC50 (μM)
Kidney: clear cell type renal cell arcinoma
Kidney; renal cell carcinoma
Kidney; clear cell type renal cell carcinoma
45. 30 (±1.0)
Kidney; clear cell type renal cell carcinoma
HNHA induced G0/G1 cell cycle arrest in RCC cells
HNHA-induced apoptosis of RCC cells was caspase-dependent
HNHA induced cytochrome c release from mitochondria and translocation from the cytoplasm to the nucleus in RCC cells
HNHA reduced the tumor burden and improved survival in RCC xenografts
HNHA suppressed in vivo tumor growth via downregulation of Bcl-2 and p-IκB and activation of caspase in RCC cells
One of the most remarkable advances in RCC treatment is the therapeutic application of anti-angiogenic therapy and mTOR inhibitors based on the important role of the HIF pathway in RCC. Most agents available today for the treatment of advanced RCC target the von Hippel-Lindau gene (VHL)/hypoxia-inducible factor (HIF) pathway . Agents targeting the vascular endothelial growth factor (VEGF) and/or mammalian target of rapamycin (mTOR) pathways continue to be the mainstay of treatment for metastatic RCC; however, durable, complete responses remain the exception. There is a continuing need for the identification of novel pathways and agents for treating RCC .
Recent progress in understanding the molecular mechanisms in RCC centers on the roles of epigenetic alterations and transcriptional deregulation. A high-throughput gene study involving solution capture and sequencing of the coding exons of 20,000 protein-coding genes identified new cancer loci, including genes encoding enzymes that demethylate/methylate key lysine residues in histone H3, which is implicated in transcriptional control by regulating chromatin structure [23,25]. Another study found truncating mutations in the PBRM1 gene, which encodes the Baf180 protein, a chromatin-targeting subunit of the SWI/SNF chromatin remodeling complex that has been implicated in multiple chromatin/transcriptionally mediated processes through interaction with histone H3, in 41% of RCC cases .
Histone modification is now a well-known epigenetic modification. Among several types of histone modification, histone deacetylation is deregulated in many cancers. A recent study revealed that HDAC1, HDAC2, and HDAC3 are highly expressed in RCC . Several studies point to overexpression of class I HDACs, in particular HDAC1, as a cancer marker associated with a poor prognosis . HDAC inhibitors have been developed to reverse gene silencing by inhibiting HDAC activity and increasing histone acetylation. These inhibitors function by binding to the catalytic site of the enzyme. There are four distinct classes of HDAC inhibitor: short-chain fatty acids (valproic acid and butyrates), hydroxamic acids (trichostatin A, TSA, and suberoylanilide hydroxamic acid), cyclic tetrapeptides (trapoxin and depsipeptide), and benzamides [28,29].
Preclinical studies have shown the potential of HDAC inhibitors in the treatment of RCC. Valproic acid (VPA) altered cell-cycle-regulating proteins, particularly CDK2, cyclin B, cyclin D3, p21, and Rb, and significantly inhibited the growth of Caki-1 in subcutaneous xenografts, accompanied by strong accumulation of p21 and Bax in tissue specimens of VPA-treated animals . Another HDAC inhibitor, SAHA, reduced the proliferation of RCC cells and augmented the activity of the mTOR inhibitor temsirolimus to induce apoptosis in xenografted RCC cell lines and depsipeptide-induced apoptosis in Caki-1, ACHN, and 786O cells, and induced G2 cell cycle arrest in 769P cells [17,31,32]. However, in contrast with the promising preclinical results, clinical trials of the HDAC inhibitors vorinostat and panobinostat have shown only modest activity in refractory metastatic RCC. In a phase II study of SAHA (vorinostat) in advanced RCC patients, SAHA showed disease stabilization in 29% patients, while a phase II trial of a different HDAC inhibitor, panobinostat, in patients with refractory metastatic RCC, failed to show an objective response [33,34]. It is difficult to evaluate the anti-tumor activity of these HDAC inhibitors for treatment-naïve advanced RCC because all participants in the study had previously been heavily treated. Nevertheless, that HDACs exist as targets and HDAC inhibitors show anti-tumor activities in RCC, but only modest activity in clinical trials, suggests that more potent HDAC inhibitors are required to achieve a clinical benefit in RCC.
In summary, we showed that HNHA had more potent anti-tumor activity than the established HDAC inhibitors SAHA and TSA with induction of apoptosis through expression of Bcl-2 and engagement of the mitochondrial pathway in RCC cells in vitro and in vivo. HNHA activated the caspase- and cytochrome-c-dependent apoptotic pathways by inducing release of cytochrome c from mitochondria and its translocation into the nucleus in RCC cells. In our study, Bax was found to be upregulated markedly by all HDAC inhibitors tested—albeit to a greater degree by HNHA than SAHA or TSA—in RCC cells. HNHA treatment resulted in the greatest level of cytochrome c release from mitochondria among the HDAC inhibitors tested.
Taken together, although the precise mechanisms of the anti-cancer effects of HDAC inhibition should be investigated further, our results suggest that HNHA may be a potent therapeutic option. The role of HDAC inhibition as an anti-cancer strategy in RCC should be evaluated using agents more potent than those tested previously.
HNHA has more potent anti-tumor activity than established HDAC inhibitors. Its effects are mediated by caspase-dependent and cytochrome-c-mediated apoptosis in RCC cells. These results suggest that HNHA may offer a new therapeutic approach to RCC.
This work was supported by grants from the National Research Foundation of Korea (2013R1A1A1005025).
- Garnis C, Buys TP, Lam WL. Genetic alteration and gene expression modulation during cancer progression. Mol Cancer. 2004;22:3–9.Google Scholar
- Kanwal R, Gupta S. Epigenetic modifications in cancer. Clin Genet. 2012;81(4):303–11.View ArticlePubMedGoogle Scholar
- Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150:12–27.View ArticlePubMedGoogle Scholar
- Füllgrabe J, Kavanagh E, Joseph B. Histone onco-modifications. Oncogene. 2011;3:3391–403.View ArticleGoogle Scholar
- Waldmann T, Schneider R. Targeting histone modifications-epigenetics in cancer. Curr Opin Cell Biol. 2013;25:184–9.View ArticlePubMedGoogle Scholar
- Johnson C, Warmoes MO, Shen X, Locasale JW. Epigenetics and cancer metabolism. Cancer Lett. 2015;356:309–14.View ArticlePubMedGoogle Scholar
- Weichert W, Röske A, Gekeler V, Beckers T, Ebert MP, Pross M, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9:139–48.View ArticlePubMedGoogle Scholar
- Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, Jung K, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008;98:604–10.View ArticlePubMedPubMed CentralGoogle Scholar
- Weichert W, Röske A, Niesporek S, Noske A, Buckendahl AC, Dietel M, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14:1669–77.View ArticlePubMedGoogle Scholar
- Chang HH, Chiang CP, Hung HC, Lin CY, Deng YT, Kuo MY. Histone deacetylase 2 expression predicts poorer prognosis in oral cancer patients. Oral Oncol. 2009;45:610–4.View ArticlePubMedGoogle Scholar
- Zhang Z, Yamashita H, Toyama T, Sugiura H, Ando Y, Mita K, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat. 2005;94:11–6.View ArticlePubMedGoogle Scholar
- Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5:769–84.View ArticlePubMedGoogle Scholar
- Molina AM, Motzer RJ, Heng DY. Systemic treatment options for untreated patients with metastatic clear cell renal cancer. Semin Oncol. 2013;40:436–43.View ArticlePubMedGoogle Scholar
- Mattei J, da Silva RD, Sehrt D, Molina WR, Kim FJ. Targeted therapy in metastatic renal carcinoma. Cancer Lett. 2014;343:156–60.View ArticlePubMedGoogle Scholar
- Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer J. 2013;19:333–40.View ArticlePubMedPubMed CentralGoogle Scholar
- Fritzsche FR, Weichert W, Röske A, Gekeler V, Beckers T, Stephan C, et al. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer. BMC Cancer. 2008;8:381.View ArticlePubMedPubMed CentralGoogle Scholar
- Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors. J Urol. 2008;180:1131–6.View ArticlePubMedGoogle Scholar
- Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. Urology. 2010;76:764. e7-13.View ArticlePubMedGoogle Scholar
- Kim DH, Lee J, Kim KN, Kim HJ, Jeung HC, Chung HC, et al. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun. 2007;356:233–8.View ArticlePubMedGoogle Scholar
- Park KC, Kim SW, Park JH, Song EH, Yang JW, Chung HJ, et al. Potential anti-cancer activity of N-hydroxy-7-(2-naphthylthio) heptanomide (HNHA), a histone deacetylase inhibitor, against breast cancer both in vitro and in vivo. Cancer Sci. 2011;102:343–50.View ArticlePubMedGoogle Scholar
- Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR Jr ZSG, Modesitt SC. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecol Oncol. 2007;104:596–601.View ArticlePubMedGoogle Scholar
- Hebbel RP, Vercellotti GM, Pace BS, Solovey AN, Kollander R, Abanonu CF, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood. 2010;115:2483–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Linehan WM, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: a metabolic disease. Nat Rev Urol. 2010;7:277–85.View ArticlePubMedPubMed CentralGoogle Scholar
- Su D, Stamatakis L, Singer EA, Srinivasan R. Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol. 2014;26:321–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature. 2010;463:360–3.View ArticlePubMedPubMed CentralGoogle Scholar
- Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifi es frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469:539–42.View ArticlePubMedPubMed CentralGoogle Scholar
- Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6:579–89.View ArticlePubMedGoogle Scholar
- Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194–202.View ArticlePubMedGoogle Scholar
- Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med. 2002;8:S43–8.View ArticlePubMedGoogle Scholar
- Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D, et al. The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med. 2009;13:2376–85.View ArticlePubMedGoogle Scholar
- Tavares TS, Nanus D, Yang XJ, Gudas LJ. Gene microarray analysis of human renal cell carcinoma: the effects of HDAC inhibition and retinoid treatment. Cancer Biol Ther. 2008;7:1607–18.View ArticlePubMedPubMed CentralGoogle Scholar
- Mahalingam D, Medina EC, Esquivel 2nd JA, Espitia CM, Smith S, Oberheu K, et al. Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels. Clin Cancer Res. 2010;16:141–53.View ArticlePubMedGoogle Scholar
- George S, Beeram M, Ricart AD, Mita AC, Brenner AJ, Ketchum N, Egorin MJ, Tolcher AW, Zwiebel JA, Sarantopoulos J. A phase II pharmacokinetic and biologic correlative study of vorinostat (suberoylanilide hydroxamic acid or SAHA) in advanced renal cell carcinoma (RCC) patients (pts). ASCO Genitourinary Cancers Symposium 2010. abstract 374Google Scholar
- Hainsworth JD, Infante JR, Spigel DR, Arrowsmith ER, Boccia RV, Burris HA. A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell carcinoma. Cancer Invest. 2011;29:451–5.View ArticlePubMedGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.